Waters Parkerson & Company increased its stake in Exxon Mobil Corp (XOM) by 2.32% based on its latest 2019Q1 regulatory filing with the SEC. Waters Parkerson & Company bought 10,387 shares as the company’s stock declined 5.48% . The institutional investor held 458,522 shares of the integrated oil company at the end of 2019Q1, valued at $37.05 million, up from 448,135 at the end of the previous reported quarter. Waters Parkerson & Company who had been investing in Exxon Mobil Corp for a number of months, seems to be bullish on the $294.04 billion market cap company. The stock decreased 0.11% or $0.08 during the last trading session, reaching $69.49. About 1.64M shares traded. Exxon Mobil Corporation (NYSE:XOM) has declined 9.03% since August 23, 2018 and is downtrending. It has underperformed by 9.03% the S&P500. Some Historical XOM News: 30/05/2018 – Exxon Hopes for New York Top Cop With Different View on Climate; 27/04/2018 – Total says first Kaombo FPSO vessel has arrived in Angola; 20/03/2018 – EXXONMOBIL CONSIDERS POLYPROPYLENE PRODUCTION EXPANSION; 01/05/2018 – SABIC and ExxonMobil Advance Gulf Coast Project with Creation of a New Joint Venture; 29/03/2018 – Federal Judge Dismisses Exxon Lawsuit Against Climate-Change Probes; 08/05/2018 – QP’S CEO SAYS WILL AWARD EPC FOR FIRST NEW LNG TRAIN BY END OF NEXT YEAR, START UP BY END OF 2023; 27/04/2018 – EXXON MOBIL CORP XOM.N SAYS ‘VERY WELL POSITIONED’ TO MEET INTERNATIONAL MARITIME ORGANIZATION HIGH-SULPUR FUEL RULE CHANGE; 20/04/2018 – Colorado counties sue Exxon, Suncor over climate change; 09/05/2018 – ALGERIA’S SONATRACH TO BUY EXXONMOBIL’S AUGUSTA OIL REFINERY IN ITALY – CEO TELLS LES ECHOS; 05/03/2018 – CERAWEEK – OPEC PLANNING ‘WORKSHOP’ ON COMPANIES THAT OPERATE IN MEMBER COUNTRIES, U.S. SHALE FIELDS -NIGERIAN ENERGY MINISTER
Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 78.1% based on its latest 2019Q1 regulatory filing with the SEC. Bvf Inc sold 5.22 million shares as the company’s stock declined 38.33% . The hedge fund held 1.46 million shares of the health care company at the end of 2019Q1, valued at $20.34 million, down from 6.69 million at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $411.25M market cap company. The stock increased 1.58% or $0.11 during the last trading session, reaching $7.06. About 20,741 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 23, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” on August 06, 2019, also Seekingalpha.com with their article: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” published on August 05, 2019, Seekingalpha.com published: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – Seeking Alpha” on June 05, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” published on August 05, 2019 as well as Globenewswire.com‘s news article titled: “ChemoCentryx Reports Second Quarter 2019 Financial Results and Recent Highlights – GlobeNewswire” with publication date: August 05, 2019.
Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It increased, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Vanguard Grp Inc has 1.29M shares for 0% of their portfolio. Alliancebernstein Ltd Partnership stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Strs Ohio stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 13,874 were accumulated by Raymond James Associate. Arrowstreet Ltd Partnership accumulated 0.01% or 324,748 shares. Minnesota-based Ameriprise has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Adams Diversified Equity Fund holds 0.01% or 15,700 shares. Moreover, Alps Advsrs has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Sg Americas Ltd Liability reported 20,240 shares or 0% of all its holdings. Goldman Sachs Grp Inc Inc stated it has 193,160 shares or 0% of all its holdings. Tiaa Cref Inv Management Limited Liability Company holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 288,597 shares. Spark Investment Management Ltd Liability Corporation holds 184,500 shares or 0.12% of its portfolio. 1.97M were reported by Carmignac Gestion. Fosun Intll Limited reported 0.08% stake. Citadel Advsrs Ltd Llc has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI).
Bvf Inc, which manages about $999.89M and $893.07 million US Long portfolio, upped its stake in Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 235,042 shares to 1.39M shares, valued at $16.72M in 2019Q1, according to the filing. It also increased its holding in Arqule Inc (NASDAQ:ARQL) by 78,328 shares in the quarter, for a total of 6.31 million shares, and has risen its stake in Alpine Immune Sciences Inc.
Waters Parkerson & Company, which manages about $1.24 billion and $1.19 billion US Long portfolio, decreased its stake in Amgen Inc Com (NASDAQ:AMGN) by 3,500 shares to 3,838 shares, valued at $729,000 in 2019Q1, according to the filing. It also reduced its holding in Johnson Ctls Intlf by 103,102 shares in the quarter, leaving it with 145,040 shares, and cut its stake in Oracle Corp Com (NYSE:ORCL).
Investors sentiment increased to 0.92 in 2019 Q1. Its up 0.28, from 0.64 in 2018Q4. It is positive, as 51 investors sold XOM shares while 747 reduced holdings. 125 funds opened positions while 607 raised stakes. 2.24 billion shares or 0.17% more from 2.24 billion shares in 2018Q4 were reported. The New York-based Chemung Canal Tru Company has invested 1.73% in Exxon Mobil Corporation (NYSE:XOM). Sequoia Financial Ltd Liability Corp accumulated 53,247 shares. Spectrum Asset Mngmt (Nb Ca) owns 27,316 shares. Aspen Investment stated it has 14,256 shares. Jefferies Grp Incorporated Ltd has invested 0.05% of its portfolio in Exxon Mobil Corporation (NYSE:XOM). The California-based Private Asset Mngmt has invested 2.19% in Exxon Mobil Corporation (NYSE:XOM). 119,143 are owned by Westchester Mgmt. Umb Natl Bank N A Mo holds 403,661 shares. Rh Dinel Invest Counsel accumulated 22,342 shares or 1.78% of the stock. Braun Stacey reported 175,387 shares or 0.94% of all its holdings. Thompson Inv, Wisconsin-based fund reported 204,575 shares. Aureus Asset Management Ltd Liability Corp reported 79,810 shares or 0.85% of all its holdings. Bingham Osborn And Scarborough Lc has invested 0.15% in Exxon Mobil Corporation (NYSE:XOM). Pinnacle Advisory Grp holds 9,123 shares or 0.05% of its portfolio. 47.77 million were reported by Fmr Ltd.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.